Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up
(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and product categories.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.